Associated Papers
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.
Febres-Aldana CA et al.
Cancer Discovery, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Murciano-Goroff YR et al.
Clinical and Translational Medicine, 2025
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_2_suppst2.pdf
Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R et al.
Cancer Communications (london, England), 2021
33630411 (PubMed )
Supplement: CAC2-41-218-s001.xlsx › Table_S3_
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E et al.
Nature Medicine, 2019
31406350 (PubMed )
Supplement: NIHMS1533563-supplement-1.xlsx › Patient_3
Select a paper to view details